News Archive: September 2026

All peptide regulatory news from September 2026.

7 Articles in September 2026

Federal Regulations September 6, 2026

The Best FDA Decision On Peptide Authorization Isn’t Yes Or No

The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...

Federal Regulations September 6, 2026

Phoenix doctor urges caution as FDA moves to regulate popular peptides

Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.

Federal Regulations September 6, 2026

FDA issues warning letters to five unapproved GLP-1 websites

FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.

Federal Regulations September 6, 2026

FDA cracks down on online black market for weight loss peptides

FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.

Federal Regulations September 6, 2026

Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding

Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and Drug Administration inspection with only one observation noted, according to a report by Sahi.

Industry News September 6, 2026

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly Files Suit Against Six Firms Over Unauthorized Retatrutide Sales Eli Lilly and Company has filed lawsuits against six companies it accuses of illegally manufacturing, marketing, and selling retatrutide, an experimental obesity and metabolic drug that has not yet received approval from the...

Industry News September 6, 2026

Qatar's Health Ministry bans trading, use or promotion of unlicensed peptide products

Qatar Health Ministry Cracks Down on Unlicensed Peptide Products Qatar's Ministry of Public Health has issued a ban on the trading, use, and promotion of unlicensed peptide products, according to a report from The Peninsula Qatar.